Publish in this journal
Journal Information
Download PDF
More article options
Original Article
DOI: 10.1016/j.reumae.2017.12.005
Available online 4 May 2019
Therapeutic impact of statins on the lipid profile and cardiovascular risk in patients with systemic lupus erythematosus: Systematic review of the literature and a meta-analysis
Impacto terapéutico de las estatinas en el perfil lipídico y el riesgo cardiovascular en pacientes con lupus eritematoso sistémico: revisión sistemática de la literatura y metaanálisis
Paula Sáncheza,
Corresponding author

Corresponding author.
, Esteban Toro-Trujilloa, Oscar M. Muñoz-Velandiab, Angel Alberto Garcíac, Daniel G. Fernández-Ávilad
a Departamento de Medicina Interna, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia
b Departamento de Medicina Interna, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia
c Departamento de Medicina Interna, Unidad de Cardiología, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia
d Departamento de Medicina Interna, Unidad de Reumatología, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia
This item has received
Article information
Full Text
Download PDF
Figures (3)
Show moreShow less
Tables (2)
Table 1. Studies included.
Table 2. Quality of the studies.
Show moreShow less

There is strong evidence of a rise in cardiovascular risk in patients suffering from autoimmune diseases, especially in those with Systemic Lupus Erythematosus. Until now, there are a few trials that assess the potencial benefit of statins on the incidence of cardiovascular events and on lipid profile of patients with SLE. This evidence has not been synthesised and assessed altogether.


We performed a search in databases of literature published until August of 2016 (Embase, MEDLINE, Cochrane Library, SciELO, Clinical Evidence, DynaMed, Cochrane Central Register of Controlled Trials, LILACS), identifying controlled clinical trials that could estimate the impact of statins on mortality, cardiovascular events, C-reactive protein and lipid profile in patients with Systemic Lupus Erythematosus. The quality of the information available was assessed with a meta-analysis, using a random effects model, employing the RevMan 5.3 software.


6 trials and 412 patients were included in the analysis. The use of statins in patients with SLE was found to significantly reduce the levels of serum total cholesterol (mean difference [MD] −31.4mg/dL; CI 95% −43.0; −19.9), and serum low density cholesterol (MD −31.4mg/dL; IC 95% −43.0; −19.9), but had no impact on levels of serum triglycerides (MD 4mg/dL; IC 95% 2.49; 6.21) and C-reactive protein (MD −0.78; IC 95% −1.43; −0.13). No evidence was found about the impact on the risk of mortality or cardiovascular events.


Statins have a significant effect on the levels of serum total cholesterol, LDL cholesterol and C-reactive protein, however, more randomised controlled trials with long-term follow-up are necessary to assess the impact on mortality and cardiovascular risk.

Systemic lupus erythematosus

Existe evidencia que muestra un aumento del riesgo cardiovascular en pacientes que padecen de enfermedades autoinmunes, en particular, de lupus eritematoso sistémico. Hasta el momento existen pocos estudios que evalúen el potencial beneficio de las estatinas en la incidencia de eventos cardiovasculares y en el perfil lipídico de pacientes con, y esta evidencia no ha sido sintetizada y evaluada en conjunto.


Se realizó una búsqueda de la literatura hasta agosto de 2016 (Embase, MEDLINE, Cochrane Library, SciELO, Clinical Evidence, DynaMed, registro de experimentos clínicos de Cochrane, LILACS), identificando ensayos clínicos controlados que evaluaran el impacto de las estatinas en mortalidad, eventos cardiovasculares, proteína C reactiva y perfil lipídico en pacientes con lupus eritematoso sistémico. Se evaluó la calidad de la información disponible y se metaanalizó utilizando un modelo de efectos aleatorios, utilizando el programa RevMan 5.3.


Un total de 6 estudios y 412 pacientes fueron incluidos para el análisis. Se encontró que el uso de las estatinas en paciente con LES reduce significativamente los niveles de colesterol total (diferencia de medias [DM] −31,2mg/dL; IC 95% −41,9; −20,5), colesterol de baja densidad (DM −31,4mg/dL; IC 95% −43,0; −19,9), sin impacto en los niveles de triglicéridos (DM 4mg/dL; IC 95% 2,49; 6,21) y proteína C reactiva (DM −0,78; IC 95% −1,43; −0,13). No se encontró ninguna evidencia sobre impacto en el riesgo de mortalidad o eventos cardiovasculares.


Las estatinas tienen un impacto significativo en los niveles de colesterol total, colesterol unido a lipoproteínas de baja densidad y proteína C reactiva, sin embargo, son necesarios nuevos estudios aleatorizados controlados con seguimiento a largo plazo para evaluar el impacto en la mortalidad y el riesgo cardiovascular.

Palabras clave:
Lupus eritematoso sistémico


These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Reumatología Clínica (English Edition)

Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.